ABSTRACT This was a prospective, placebo-controlled, single-blind trial of moricizine (ethmozine) in a dose averaging 10 mg/kg/day in 50 patients, the single entrance 
IN SPECIFIC patient populations, especially patients with recent myocardial infarction, the presence of frequent and complex ventricular arrhythmias detected by ambulatory electrocardiographic (ECG) recording identifies a subgroup at increased risk for sudden cardiac death.'-' Additionally, patient populations characterized by complex ventricular arrhythmia, especially nonsustained ventricular tachycardia (VT), and left ventricular dysfunction are at increased risk for sudden death.i7 In contrast, relatively healthy subjects with frequent and complex ventricular arrhythmia appear to be at minimal risk for sudden cardiac death.8 The rhythm disturbance responsible for sudden death ap-pears to be VT and ventricular fibrillation in the majority of patients.9 10 Although (3-blockers reduce sudden death mortality after myocardial infarction, their usefulness is limited in patients withl severely depressed left ventricular function. -14 Despite the widespread use of type I antiarrhythmics, none have been shown to reduce the incidence of sudden death in any high-risk population. '5 There are multiple shortcomings of the currently available antiarrhythmic drugs. First, the presently available type I antiarrhythmics have limited efficacy in suppressing premature ventricular complexes (PVCs). They also possess frequent side effects and potentially serious toxicity and they may significantly depress left ventricular function. '2 Antiarrhythmic drugs frequently worsen existing ventricular arrhythmia, even causing torsade de pointes VT,23 :' with reported frequencies of "arrhythmia aggravation" up to 16% in high-risk patients .32 In published studies by our group and others, moricizine (ethmozine) has a number of desirable characteristics meriting further investigation as a new antiarrhythmic agent. [33] [34] [35] [36] Moricizine is a phenothiazine derivative that effectively suppresses PVCs and has minimal effect on the QT interval of the scalar electrocardiogram. Importantly, moricizine has a low incidence of minor side effects. 35 36 Serious toxicity has not been reported. However, all previous studies, including our published experience, are limited by the selection of patients with relatively benign, non-lifethreatening ventricular arrhythmia who have preserved ventricular function. 33 36 The effectiveness of moricizine in a patient population with VT and left ventricular dysfunction has not been previously reported. The goal of this clinical trial was to select patients with frequent nonsustained VT and to characterize their response to the long-term administration of moricizine, with drug efficacy defined by reduction in runs of nonsustained VT quantified on ambulatory ECG recording.
Methods
Study design. This was a prospective, single-blind, placebocontrolled trial of 50 patients. The sole entrance criterion was the presence of 10 or more runs of nonsustained VT on a single 24 hr ambulatory ECG recording. All qualifying ambulatory ECG recordings were performed at least 5 days after discontinuation of antiarrhythmic drug therapy, and patients were excluded if they had undergone prior investigational antiarrhythmic therapy. A previous history of sudden cardiac death or demonstration of previous sustained VT was not an exclusion criteria for this trial.
The details of study design are illustrated in figure 1. This protocol was approved by the Baylor Institutional Review Board in November 1982, and enrollment of patients was begun in December 1982. After eligibilivy was established and informed consent obtained, all patients were hospitalized in the General Clinical Research Center, where placebo ambulatory ECG recording was performed over 3 days for baseline quantification of ventricular arrhythmia.
Ambulatory ECG recordings were used as the sole end point to judge the efficacy of moricizine. Electrophysiologic study was not part of the study protocol. Therapeutic success was defined as a 75% or greater reduction in the mean daily runs of VT as detected by serial ambulatory ECG recordings. Moricizine was begun at a dosage of 10 mg/kg/day in three daily doses and never exceeded 14.6 mg/kg/day. Failure to achieve a 75% Inpatient Placebo Days 1 2 3 4 or greater reduction of the mean runs of VT was considered a therapeutic failure, resulting in withdrawal of the patient. A second criterion for withdrawal was the occurrence of sustained VT (defined as VT >120 beats/min for >30 sec that required drug intervention or cardioversion for resumption of normal sinus rhythm). Aggravation of arrhythmia by moricizine was defined as a 400% or greater increase in runs of VT or as an episode of sustained VT in any patient with no previous episode, criteria more strict than those of Velebit et al.32 No patients were lost to follow-up, and sudden cardiac deaths (defined as death in <1 hr from the onset of symptoms) were documented carefully.
Patients. This study reports results from 50 consecutive patients, mean age 57 + 10 years, including 42 men and eight women. The mean follow-up was 6 months (range I to 24). Sixty percent of patients were taking digitalis, 6% fl-blockers, and 6% calcium antagonists. Twenty patients (40%) had prior documentation of sustained VT. Of these, 19 had ECG documentation of sustained monomorphic VT and one had polymorphic VT and cardiac arrest. In all cases the episodes of sustained VT had required intervention (drug or cardioversion). The range of VT rates was between 140 and 210 beats/min. Patients had failed an average of two conventional antiarrhythmic drugs before enrollment in the study.
Thirty-one patients (62%) had a diagnosis of coronary artery disease. Of these, 27 (87%) had previous myocardial infarction (defined as having appropriate history and ECG changes with positive creatine kinase MB isoenzyme findings). The diagnosis of coronary artery disease was established in 77% (24/31) of these patients by cardiac catheterization, with angiographic demonstration of a 70% or greater luminal narrowing of one or more major coronary artery. The diagnosis of coronary artery disease in the remaining seven patients was established by ECG evidence of myocardial infarction as well as by the demonstration of a segmental wall motion defect on two-dimensional echocardiographic examination. Cardiac diagnosis in the remaining 19 patients was established by cardiac catheterization in 14 and by a combination of clinical and two-dimensional echocardiographic findings in the remaining five patients. Diagnoses included mitral valve prolapse (four patients), dilated cardiomyopathy (four patients), and hypertensive cardiomyopathy (three patients); eight patients had no demonstrable organic heart disease.
Ambulatory ECG recording. Ambulatory ECG recordings were performed on Avionics 440B tape recorders and analyzed on an Avionics Trendsetter (lrvine, CA). Each 24 hr ambulatory ECG recording was analyzed hourly for the prevalance of PVCs, couplets, and runs of VT. All ambulatory ECG tapes were edited by a cardiologist. Quality control in our laboratory using standard test tapes shows a reproducibility of 92% for Moricizine 5 6 PVCs, 95% for couplets and 98% for VT runs (intraobserver variability). Agreement in PVC counts between two research ambulatory electrocardiographic scanners is 95% (interobserver variability). External quality control from the core laboratory of a national arrhythmia trial has verified a 95% or greater agreement in the detection of runs of VT. Two-dimensional echocardiographic assessment of left ventricular function. Left ventricular ejection fraction (LVEF) was assessed by two-dimensional echocardiography with an ATL Mark V sector scanner equipped with a slow-motion, frame-by-frame, bidirectional playback video recorder. LVEF was determined from the average of several diameters measured in multiple views with the method previously validated in our laboratory. 37 Moricizine plasma levels. Plasma levels of moricizine were determined by the absorption spectrometric method after highpressure liquid chromatographic separation as detailed in previous reports. 35 36 Peak and trough plasma moricizine samples (1 hr after and 1 hr before dose, respectively) were obtained weekly for the first month of therapy and then every 3 months in patients remaining in the trial.
Statistical analysis. For comparison of paired data, a twotailed t test was performed if normality could be assumed. If normality could not be assumed, Wilcoxon signed ranks tests were performed. Analysis was carried out with the natural log (In+ l) of arrhythmia frequency to produce a more normal distribution.
Results
Arrhythmia data at baseline. ular function is represented in figure 3 . Approximately one-half of the patient population had LVEFs less than 40%. Of the 20 patients presenting with sustained VT, 14 had LVEFs under 40% (figure 3).
Initial response to moricizine. A summary of the results of the in-hospital portion of the protocol is diagrammed in figure 4 . Of the 50 patients entering the trial, two dropped out during the placebo therapy. Moricizine was initially effective in 35 of 48 (73%) as judged by a 75% or greater reduction in runs of VT (figure 4). Two of these patients, however, dropped out before hospital discharge because of lack of cooperation with the trial. An additional 13 patients failed to complete the in-patient portion of the trial. One patient developed intercurrent myocardial infarction on day 4 of moricizine, and a second patient developed congestive heart failure. The latter patient had been taking digitalis and diuretics and had an LVEF of 30%. He died of progressive congestive heart failure. Six patients with a history of sustained VT before therapy with moricizine had early recurrent episodes of sustained VT; one died suddenly. Additionally, five patients failed to achieve the protocol requirement of a 75% or greater reduction in runs of nonsustained VT (figure 4). One of these patients had a 532% increase in nonsustained VT frequency while on moricizine (from 262 to 1394 runs of VT per day).
The arrhythmia frequencies for the 33 patients discharged on moricizine are summrized in table 1. Compared with placebo, there was an 81 % reduction in PVCs, a 91% reduction in couplets, and a 99% reduction in runs of VT, all highly significant (p < .001).
Outpatient response to moricizine. The individual outcomes of the 33 patients discharged on moricizine are summarized in figure 5. There were two deaths on moricizine before the 1 month follow-up visit. One patient with historical documentation of sustained VT died suddenly. A second patient with a long history of congestive heart failure was hospitalized because of As seen in figure 5 , an additional eight patients were dropped from the trial between the first and third months. Six of these patients were withdrawn because of drug failure. One of these patients with a history of sustained VT died suddenly while on moricizine. Three patients had recurrent sustained VT. One patient had an increase in nonsustained VT on moricizine (from 4 to 328 runs of VT per day) and was dropped from the trial.
A total of 22 patients received moricizine for 3 months or longer (figure 5). One Long-term follow-up for patients on moricizine (>6 months). Of the 18 patients followed for 6 months or longer, one died overnight at home after 10 months Side effects and toxicity of moricizine. Patients were questioned about any new symptoms at each clinic visit. Compared with placebo there was an increase of mild nausea during therapy with moricizine (6/48 on placebo vs 17/48 on moricizine; p < .01). However, this comparison is between 3 days of placebo and an average of 6 months of moricizine. This side effect was transient and never resulted in discontinuation of therapy. Importantly, no other side effect was increased significantly during therapy with moricizine. No patient was withdrawn from the trial because of drug intolerance. Transient elevations of LDH enzyme occurred early in three patients on moricizine but these resolved. No other hepatic, renal, or hematopoetic variables changed with moricizine. Congestive heart failure worsened significantly in two patients during initiation of moricizine as previously described. In both cases clinically significant deterioration of left ventricular function was not reflected by dramatic changes in two-dimensional echocardiographic assessment of LVEF, which changed 0% and 2%, respectively, with moricizine and placebo. These two patients demonstrate the lack of sensitivity of global LVEF in detecting clinically important hemodynamic alterations that might be caused by antiarrhythmic therapy. There were no statistically significant changes in PR and QRS intervals on the resting electrocardiogram (0.18 ± 0.02 and 0. 10 + 0.01 sec, respectively). Likewise, QT intervals were unchanged (0. 36 sec on placebo and moricizine). No patient had an increase in QT interval of 0.03 sec or more. Worsening of arrhythmia occurred during therapy with moricizine in five patients. Two had dramatic increases in frequency of runs of Efficacy of moricizine in patients with sustained VT. Although moricizine was effective in suppressing nonsustained VT in the majority of patients, it was ineffective in preventing the recurrence of sustained VT. The majority of these patients (12/19) had recurrence of sustained VT either before hospital discharge or within the first month of therapy. An interesting observation in this group was that the extent of suppression of nonsustained VT on ambulatory ECG monitoring during therapy with moricizine was not predictive of prevention of sustained VT or subsequent sudden death. In fact, total abolition of runs of nonsustained VT on moricizine was seen as frequently in patients who subsequently had recurrent sustained VT as it was in patients free of recurrence for an average of 6 months.
Tolerance of moricizine in patients with left ventricular dysfunction. Despite the depressed left ventricular function in this study group (mean LVEF 36%), hemodynamic deterioration on moricizine occurred in only two patients. These two patients (with LVEFs, of 18% and 30%) were the exception to the rule, since an additional 21 patients had LVEFs of 30% or less and tolerated moricizine well without clinical deterioration. Thus, in the majority of patients, moricizine in dosages up to 14 mg/kg/day did not appear to alter the clinical or echocardiographic assessment of left ventricular function.
Antiarrhythmic response relative to initial left ventricular function. An important observation from this trial is that patients' antiarrhythmic responses to moricizine were related to the initial LVEF. Patients who were dropped from the trial because of failed arrhythmia suppression tended to be those with LVEFs of 30% or less despite an apparent lack of adverse effect on ventricular function, whereas patients responding to moricizine were those whose LVEFs were 40% or greater.
These differences were statistically significant at both the 1 and 3 month intervals during the trial ( Side effects and "arrhythmia aggravation" due to moricizine. This study extends observations made in our previously published investigations of moricizine in patients with stable non-life-threatening arrhythmias. 35 Moricizine is well tolerated with a low incidence of minor side effects. It can be safely used in the majority of patients with left ventricular dysfunction. Although some patients report mild gastrointestinal disturbances, these complaints are not of a serious nature to require discontinuation of therapy. The only serious toxicity we observed in our study was the development of clinical congestive heart failure in two patients. Therefore, as with most clinically available antiarrhythmic drugs, administration of moricizine in patients with LVEFs of 30% or less should be done under close observation, but the drug will usually be well tolerated. "Arrhythmia aggravation" has recently been defined by Velebit et alY32 to include: (1) fourfold increase in PVCs, (2) a 10-fold increase in couplets or nonsustained VT, or (3) first occurrence of sustained VT not present during control studies. By our more strict criteria, "arrhythmia aggravation" occurred in two of 48 (4%). However, three patients with prior sustained VT had sudden cardiac death during therapy with moricizine. Whether this represented drug inefficacy or whether moricizine actually worsened the arrhythmia is speculative; but if these patients are considered to have had "arrhythmia aggravation" this results in a 10.4% incidence, comparable with other antiarrhythmic drugs reported by Velebit et al. 32 In summary, moricizine is effective in suppressing runs of nonsustained VT in approximately two-thirds of patients presenting with frequent nonsustained VT. Moricizine is less effective in patients with sustained VT and in fact prevented recurrence of sustained VT in only 37% of patients. However, it is a well-tolerated drug, even in patients with significant left ventricular dysfunction, with a low incidence of minor side effects and serious toxicity. Moricizine appears to be a safe and effective alternative drug in the treatment of nonsustained VT.
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